Search research articles
Contact Us
Filters
Showing results (31-40 of 53) with videos related to
Page
of 6
Sort By:
British Journal of Haematology
|
December 21, 2002
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II
John Shaughnessy, Erming Tian, Jeffrey Sawyer, et al.
Blood
|
January 27, 2005
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
Frits van Rhee, Susann M Szmania, Fenghuang Zhan, et al.
American Journal of Hematology
|
March 5, 2013
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
Rakesh Bam, Wen Ling, Sharmin Khan, et al.
Blood
|
December 3, 2005
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
Bart Barlogie, Guido Tricot, Erik Rasmussen, et al.
British Journal of Haematology
|
April 3, 2003
CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease
Jeroen E J Guikema, Sjoerd Hovenga, Edo Vellenga, et al.
Oncogene
|
July 27, 2005
ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma
Atsushi Suzuki, Shinsuke Iida, Miyuki Kato-Uranishi, et al.
Blood
|
August 1, 2002
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts
Karin Tarte, John De Vos, Thomas Thykjaer, et al.
Bone Marrow Transplantation
|
April 17, 2025
Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience
Bhavesh Mohan Lal, Toshali Pandey, Marah Alzubi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2004
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients
Naoko Takebe, Xiangfei Cheng, Suhlan Wu, et al.
American Journal of Hematology
|
August 7, 2024
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma
Samer Al Hadidi, Obada Ababneh, Carolina Schinke, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 53) with videos related to
Sort By:
Page
of 6
British Journal of Haematology
|
December 21, 2002
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II
John Shaughnessy, Erming Tian, Jeffrey Sawyer, et al.
Blood
|
January 27, 2005
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
Frits van Rhee, Susann M Szmania, Fenghuang Zhan, et al.
American Journal of Hematology
|
March 5, 2013
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
Rakesh Bam, Wen Ling, Sharmin Khan, et al.
Blood
|
December 3, 2005
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
Bart Barlogie, Guido Tricot, Erik Rasmussen, et al.
British Journal of Haematology
|
April 3, 2003
CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease
Jeroen E J Guikema, Sjoerd Hovenga, Edo Vellenga, et al.
Oncogene
|
July 27, 2005
ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma
Atsushi Suzuki, Shinsuke Iida, Miyuki Kato-Uranishi, et al.
Blood
|
August 1, 2002
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts
Karin Tarte, John De Vos, Thomas Thykjaer, et al.
Bone Marrow Transplantation
|
April 17, 2025
Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience
Bhavesh Mohan Lal, Toshali Pandey, Marah Alzubi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2004
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients
Naoko Takebe, Xiangfei Cheng, Suhlan Wu, et al.
American Journal of Hematology
|
August 7, 2024
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma
Samer Al Hadidi, Obada Ababneh, Carolina Schinke, et al.
Page
of 6